TSX symbol: SBS
CALGARY, Feb. 11 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that Andrew Baum, President and Chief Executive Officer of the Company, will be presenting a corporate update at the 10th Annual BIO CEO & Investor Conference on Wednesday, February 13, 2008 at the Waldorf Astoria Hotel in New York City. Mr. Baum's presentation is scheduled at 3:30 P.M. ET in the Jade Room. A live webcast of the presentation will be available by visiting the SemBioSys homepage at http://www.sembiosys.com.
For more information on the BIO CEO & Investor Conference, visit the conference website at http://ceo.bio.org.
About SemBioSys Genetics Inc. (http://www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's cur
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved